Clinical

Morphic’s EMERALD-1 trial for ulcerative colitis disappoints

Investors have raised a concern about Morphic's eagerly awaited EMERALD-1 trial. Despite experiencing an initial surge in stock values following the release...

Ionis sees success in lipid reduction Phase 3 trial

Ionis Pharmaceuticals has achieved a significant milestone in their phase 3 clinical trial focused on therapies that reduce lipids. This achievement positions...

Phase 3 trial data for Astellas’s GA drug yielded positive results

A mere six weeks after obtaining FDA approval, Astellas Pharma is already considering expanding the label for Izervay, an eye injection acquired...

With the trial’s success, AbbVie prepares Botox for a different aesthetic use

Recently, AbbVie disclosed positive outcomes from a second phase 3 trial of Botox, aimed at managing moderate to severe platysma prominence. This...

Blackstone’s $250 million investment in ex-Novartis assets pays off

Blackstone Life Sciences' substantial $250 million investment in Anthos Therapeutics' abelacimab, formerly known as MAA868 has yielded promising results. Novartis initially introduced...

Arbutus Halts COVID-19 RNA Destabilization Projects After Reviewing Early Preclinical Data

Arbutus Biopharma has undertaken a substantial shift in its strategic direction, opting to withdraw from its involvement in COVID-19 research and discontinue...

Novocure’s TTFields Misses the Mark in Phase 3 Ovarian Cancer Trial

In a striking departure from earlier this year's promising findings, Novocure's groundbreaking technology known as Tumor Treating Fields (TTFields) has encountered a...

BridgeBio Explores Phase 3 Acoramidis Data in Depth

BridgeBio is delving deeper into the phase 3 research of acoramidis, focusing on individuals suffering from transthyretin amyloid cardiomyopathy (also known as...

Latest news

Morphic’s EMERALD-1 trial for ulcerative colitis disappoints

Investors have raised a concern about Morphic's eagerly awaited EMERALD-1 trial. Despite experiencing an initial surge in...

Ionis sees success in lipid reduction Phase 3 trial

Ionis Pharmaceuticals has achieved a significant milestone in their phase 3 clinical trial focused on therapies that...

Overcoming Age-Related Challenges in Nanodrug Delivery for Pediatric Cancer Patients

The efficacy of medical treatments often varies with age, and this principle holds true in the world...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

China forces insulin price cuts resulting in pullback for global pharma players

Xinhua, a Chinese news channel, commented on...

BioNTech receives $90 million from CEPI partnership

BioNTech is in the midst of conducting...